Literature DB >> 16318953

Dextromethorphan psychosis, dependence and physical withdrawal.

Shannon C Miller1.   

Abstract

As part of a synthesis of evidence regarding the abuse and addiction liability of dextromethorphan (DM), an over-the-counter cough medicine available in over 140 preparations, an uncommonly published case of dextromethorphan dependence (addiction) is described, with specific, rarely published complications. The individual was interviewed and several medical databases were also reviewed (Medline, 1966-present; PubMed) for all content relating to the Keywords: dextromethorphan, abuse, dependence, cough medicine, addiction, withdrawal, psychosis. The patient evidenced history suggesting substance dependence, substance-induced psychosis and substance withdrawal in relation to DM. A literature review revealed that DM has specific serotonergic and sigma-1 opioidergic properties. Dextrorphan (DOR), the active metabolite of DM, has similar properties; however, DOR is a weaker sigma opioid receptor agonist, and a stronger NMDA receptor antagonist. DM and DOR display specific biological features of addiction, and are capable of inducing specific psychiatric sequelae. A specific, reproducible toxidrome with significant psychiatric effects occurred, when DM was abused at greater than indicated doses, with more profound and potentially life-threatening effects at even higher doses. DM withdrawal appears evident. DM's active metabolite, DOR, has pharmacodynamic properties and intoxication effects similar to dissociatives, and may be more responsible for the dissociative effect that this DM abuser sought. However, it is this same metabolite that may be fraught with the potentially life-threatening psychoses and dissociative-induced accidents, as well as addiction. While DM has been hypothesized as the most commonly abused dissociative, health-care providers seem largely unaware of its toxidrome and addiction liability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16318953     DOI: 10.1080/13556210500352410

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  17 in total

1.  Naloxone can act as an analgesic agent without measurable chronic side effects in mice with a mutant mu-opioid receptor expressed in different sites of pain pathway.

Authors:  Shu-Husan Chou; Jen-Hsin Kao; Pao-Luh Tao; Ping-Yee Law; Horace H Loh
Journal:  Synapse       Date:  2012-03-31       Impact factor: 2.562

2.  Glioblastoma: looking at the currently marketed sigma-1 agonists and antagonists.

Authors:  Richard E Kast
Journal:  Neoplasia       Date:  2007-08       Impact factor: 5.715

3.  Novel psychoactive substances of interest for psychiatry.

Authors:  Fabrizio Schifano; Laura Orsolini; G Duccio Papanti; John M Corkery
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

4.  A case of acute psychosis secondary to coricidin overdose.

Authors:  Siva Kumar Aytha; Srinivas Dannaram; Swapna Moorthy; Ashish Sharma
Journal:  Prim Care Companion CNS Disord       Date:  2013

5.  Dextromethorphan in Cough Syrup: The Poor Man's Psychosis.

Authors:  Bridgette Martinak; Ramy A Bolis; Jeffrey Ryne Black; Rachel E Fargason; Badari Birur
Journal:  Psychopharmacol Bull       Date:  2017-09-15

6.  Ten Years of Robotripping: Evidence of Tolerance to Dextromethorphan Hydrobromide in a Long-Term User.

Authors:  Travis D Olives; Sean P Boley; Jenna M LeRoy; Samuel J Stellpflug
Journal:  J Med Toxicol       Date:  2019-03-22

7.  A cross-sectional examination of medicinal substance abuse and use of nonmedicinal substances among Canadian youth: findings from the 2012-2013 Youth Smoking Survey.

Authors:  Cesar Leos-Toro; David Hammond; Stephen Manske
Journal:  CMAJ Open       Date:  2015-11-09

8.  Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.

Authors:  Melanie A Paquette; Elizabeth G Brudney; Daniel B Putterman; Charles K Meshul; Steven W Johnson; Stephen Paul Berger
Journal:  Neuroreport       Date:  2008-01-08       Impact factor: 1.837

9.  The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.

Authors:  Melanie A Paquette; Katherine Foley; Elizabeth G Brudney; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Psychopharmacology (Berl)       Date:  2009-03-13       Impact factor: 4.530

10.  Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.

Authors:  Melanie A Paquette; Alex A Martinez; Teresa Macheda; Charles K Meshul; Steven W Johnson; S Paul Berger; Andrea Giuffrida
Journal:  Eur J Neurosci       Date:  2012-08-03       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.